SFCM
MLYS icon

Seven Fleet Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Seven Fleet Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88M Buy
69,571
+27,546
+66% +$808K 0.59% 40
2025
Q4 		$1.53M Buy
+42,025
New +$1.69M 1.03% 17

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Seven Fleet Capital Management's MLYS Position: Q1 2026 in Review

Seven Fleet Capital Management increased its Mineralys Therapeutics (MLYS) stake by 66% in Q1 2026, buying an estimated $808K and bringing the position to 69,571 shares worth $1.88M. The position accounts for 0.59% of the portfolio, ranked #40.

Seven Fleet Capital Management first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Seven Fleet Capital Management held 69,571 shares of Mineralys Therapeutics worth $1.88M as of Q1 2026.
  • Seven Fleet Capital Management bought 27,546 Mineralys Therapeutics shares in Q1 2026, an estimated $808K.
  • Mineralys Therapeutics made up 0.59% of Seven Fleet Capital Management's portfolio in Q1 2026, its #40 holding.
  • Seven Fleet Capital Management first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.